VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASCO 2020 | EVOLVE: Orva-cel in RRMM

Sham Mailankody, MBBS, Memorial Sloan Kettering Cancer Center, New York City, NY, USA, discusses data from the EVOLVE phase 1/2 study (NCT03430011) of orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR-T cell therapy, in patients with relapsed/refratory multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter